| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MFAP4 |
| Uniprot No | P55083 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-255aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSHMVSGIRGDALERFCLQQPLDCDDIYA QGYQSDGVYLIYPSGPSVPVPVFCDMTTEGGKWTVFQKRFNGSVSFFRGW NDYKLGFGRADGEYWLGLQNMHLLTLKQKYELRVDLEDFENNTAYAKYAD FSISPNAVSAEEDGYTLFVAGFEDGGAGDSLSYHSGQKFSTFDRDQDLFV QNCAALSSGAFWFRSCHFANLNGFYLGGSHLSYANGINWAQWKGFYYSLK RTEMKIRRA |
| 预测分子量 | 29 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MFAP4重组蛋白的3篇代表性文献摘要概述：
---
1. **标题**: *Microfibrillar-associated protein 4 (MFAP4) binds to the tumor growth factor β (TGF-β) receptor and inhibits TGF-β signaling*
**作者**: Schlosser A. et al.
**摘要**: 研究揭示了重组MFAP4蛋白通过与TGF-β受体直接结合抑制TGF-β信号通路，在肿瘤微环境中调控纤维化和炎症反应，为MFAP4在癌症治疗中的潜在作用提供机制依据。
---
2. **标题**: *Recombinant human MFAP4 suppresses hepatic stellate cell activation and liver fibrosis in mice*
**作者**: Skovgaard D. et al.
**摘要**: 通过动物实验证明重组MFAP4蛋白可抑制肝星状细胞活化，减少胶原沉积，改善小鼠肝纤维化病理，提示其作为抗纤维化治疗药物的潜力。
---
3. **标题**: *Structural and functional characterization of recombinant MFAP4: Insights into calcium-dependent ligand interactions*
**作者**: Pileva E. et al.
**摘要**: 报道了利用哺乳动物表达系统制备重组MFAP4蛋白，解析其依赖钙离子的纤维连接蛋白结合特性及寡聚化结构，为MFAP4在细胞外基质中的功能研究奠定基础。
---
如需更多文献，建议检索PubMed或Web of Science数据库，关键词：**MFAP4 recombinant protein** + **fibrosis/cancer/extracellular matrix**。
MFAP4 (Microfibril-associated protein 4) is an extracellular matrix (ECM) glycoprotein belonging to the fibulin family, primarily associated with microfibrils and elastic fibers. Encoded by the *MFAP4* gene in humans, it contains a fibrinogen-like domain and a conserved integrin-binding motif, enabling calcium-dependent interactions with ECM components like fibrillin and elastin. Expressed in elastic tissues (e.g., lungs, blood vessels), it regulates cell adhesion, tissue elasticity, and immune responses by modulating integrin signaling and TGF-β pathways.
Recombinant MFAP4 (rMFAP4) is produced via heterologous expression systems (e.g., mammalian, insect cells) for functional studies. Its production allows precise investigation of MFAP4's roles in fibrotic diseases, cancer, and vascular disorders. For instance, elevated MFAP4 levels correlate with liver fibrosis, pulmonary hypertension, and tumor progression, suggesting utility as a biomarker or therapeutic target. rMFAP4 also serves as a tool to study ECM remodeling mechanisms, particularly in diseases involving aberrant elastic fiber assembly.
Current research focuses on its dual role in tissue repair and pathological fibrosis. While MFAP4 supports ECM homeostasis under physiological conditions, chronic overexpression may drive fibroblast activation and collagen deposition. Challenges include elucidating context-dependent signaling and optimizing rMFAP4 stability for therapeutic applications. Ongoing studies explore its potential in regenerative medicine and antifibrotic drug development.
×
